Product image of Icatibant Fresenius (Icatibant Acetate) supplied by GNH India

Icatibant Fresenius

Active Ingredient:
Icatibant Acetate
Origin:
EU

Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous solution for subcutaneous injection. It is used to treat acute attacks of hereditary angioedema in patients with a confirmed diagnosis, providing rapid symptom relief.

GNH India supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards. The company ensures product integrity through validated cold‑chain logistics and comprehensive quality assurance.

Manufacturer / TM Owner

Fresenius Kabi Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant Fresenius is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema.

  • Acute attacks of hereditary angioedema type I: rapid reduction of swelling and pain.
  • Acute attacks of hereditary angioedema type II: rapid reduction of swelling and pain.
  • Acute attacks of hereditary angioedema with normal C1‑INH: rapid reduction of swelling and pain.

How It Works

  • Icatibant acetate selectively blocks the bradykinin B2 receptor, preventing bradykinin from binding and activating the receptor. This inhibition stops bradykinin‑mediated vasodilation and increased vascular permeability, thereby reducing the edema and pain associated with hereditary angioedema attacks.

Side Effects

Common adverse reactions observed with subcutaneous icatibant include injection‑site and systemic events.

Common Side Effects

  • Injection site pain: discomfort at the injection site.
  • Injection site erythema: redness around the injection area.
  • Injection site swelling: localized edema.
  • Nausea: feeling of sickness.
  • Headache: mild to moderate head pain.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reaction: rash, itching, or hives.
  • Anaphylaxis: severe, potentially life‑threatening allergic response.
  • Angioedema: swelling of face, lips, or throat.
  • Severe hypotension: marked drop in blood pressure.
  • Severe injection‑site necrosis: tissue damage at injection site.

Precautions & Warnings

Before using icatibant, consider the following safety measures.

  • Pregnancy: safety not established; discuss risks with a healthcare professional.
  • Breastfeeding: unknown safety; weigh benefits against potential risks.
  • Renal impairment: use with caution and monitor renal function.
  • Concomitant ACE inhibitors: may increase bradykinin levels; monitor for angioedema.
  • Known hypersensitivity: avoid use in patients with documented allergy to icatibant.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medications that affect bradykinin pathways or cardiovascular function.

Major Interactions (Avoid)

  • ACE inhibitors: additive bradykinin effects may raise angioedema risk.
  • Angiotensin receptor blockers: similar potential for increased bradykinin.
  • Other bradykinin B2 antagonists: no added therapeutic benefit.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may mask signs of infection.
  • Antihistamines: could interfere with assessment of allergic reactions.
  • Diuretics: monitor blood pressure and electrolyte balance.

Frequently Asked Questions

Icatibant Fresenius is indicated for the treatment of acute attacks of hereditary angioedema (HAE). It works by rapidly reducing swelling and pain associated with HAE episodes, providing prompt symptom relief in patients with confirmed diagnoses.

Icatibant acetate is a selective bradykinin B2 receptor antagonist. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are key mechanisms driving the swelling seen in hereditary angioedema attacks.

The dosage and administration schedule for Icatibant Fresenius are determined by the prescribing healthcare professional based on the patient’s condition, severity of the attack, and clinical guidelines. Patients should follow the prescriber’s instructions precisely.

Safety data for icatibant in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing to pregnant or breastfeeding women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies may be C1‑esterase inhibitor concentrates or kallikrein inhibitors. Icatibant offers a subcutaneous route and rapid onset, making it suitable for self‑administration during acute attacks, while alternative agents often require intravenous infusion.

Icatibant Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and efficacy.

Icatibant is administered by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe angioedema, and marked hypotension. Patients should be monitored for signs of allergic response or sudden blood pressure changes after administration.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation components. Caution is also advised for patients with severe renal impairment or those taking ACE inhibitors without medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT